Literature DB >> 19038430

Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort.

Basir Tareen1, Alex Sankin, Guilherme Godoy, Steve Temkin, Herbert Lepor, Samir S Taneja.   

Abstract

OBJECTIVES: To assess the prevalence and pathologic features of men with unilateral prostate cancer at radical prostatectomy (RP), because it has recently been proposed that men with small-volume, well-differentiated, unilateral prostate cancer can be treated with focal therapy.
METHODS: The records of 1467 consecutive men who underwent open RP by a single surgeon from January 2000 to June 2007 were reviewed after institutional review board approval. The RP pathologic reports were analyzed to determine the frequency of unilateral or bilateral disease, surgical margin status, presence of extracapsular extension, seminal vesicle invasion, Gleason score, percentage of tumor involvement (PTI), prostate-specific antigen (PSA) level, and prostate volume. Logistic regression analysis was performed to analyze the relationship between these factors and the detection of unilateral disease.
RESULTS: Unilateral cancer was identified in 313 of 1467 patients (21.3%). Of these patients, 206 had a PTI of < or = 5%, 40 had a PTI of 5%-10%, 8 had a PTI of 10%-15%, and 40 had a PTI > 15%. The factors significantly associated with unilateral disease on univariate analysis were PTI, PSA level, pathologic Gleason score, seminal vesicle invasion, and extracapsular extension. The PSA level and seminal vesicle invasion remained significant predictors on multivariate analysis. Overall, 163 men (11.1%) had unilateral, low-risk disease (defined as a PSA level < 10 ng/mL, Gleason score < 7, and PTI < 10%).
CONCLUSIONS: Although candidates for focal therapy exist among men undergoing RP within a contemporary cohort, they represent a small minority. Before proceeding with focal therapy, the urology community must identify accurate methods of candidate selection.

Entities:  

Mesh:

Year:  2008        PMID: 19038430     DOI: 10.1016/j.urology.2008.08.504

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  9 in total

Review 1.  Robotic prostate biopsy and its relevance to focal therapy of prostate cancer.

Authors:  Henry Ho; John S P Yuen; Christopher W S Cheng
Journal:  Nat Rev Urol       Date:  2011-09-20       Impact factor: 14.432

2.  Focal therapy: a new paradigm for the treatment of prostate cancer.

Authors:  Basir Tareen; Guilherme Godoy; Samir S Taneja
Journal:  Rev Urol       Date:  2009

3.  Focal therapy for prostate cancer - where are we in 2011?

Authors:  Michael S Borofsky; Timothy Ito; Andrew B Rosenkrantz; Samir S Taneja
Journal:  Ther Adv Urol       Date:  2011-08

4.  PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: impact on hemiablative focal therapy.

Authors:  Thomas Hofner; Jesco Pfitzenmaier; Adel Alrabadi; Sascha Pahernik; Boris Hadaschik; Nina Wagener; Nenad Djakovic; Axel Haferkamp; Markus Hohenfellner
Journal:  World J Urol       Date:  2010-12-31       Impact factor: 4.226

Review 5.  An update on focal therapy for prostate cancer.

Authors:  Marlon Perera; Nishanth Krishnananthan; Uri Lindner; Nathan Lawrentschuk
Journal:  Nat Rev Urol       Date:  2016-09-27       Impact factor: 14.432

6.  Anatomically versus biologically unifocal prostate cancer: a pathological evaluation in the context of focal therapy.

Authors:  Markos Karavitakis; Hashim U Ahmed; Paul D Abel; Steven Hazell; Mathias H Winkler
Journal:  Ther Adv Urol       Date:  2012-08

7.  Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.

Authors:  J W F Catto; M C Robinson; P C Albertsen; J R Goepel; M F Abbod; D A Linkens; M Davis; D J Rosario; A Y Warren; M Varma; D F Griffiths; K M Grigor; N J Mayer; J D Oxley; N S Deshmukh; J A Lane; C Metcalfe; J L Donovan; D E Neal; F C Hamdy
Journal:  Br J Cancer       Date:  2011-08-23       Impact factor: 7.640

8.  Combination of clinical characteristics and transrectal ultrasound-guided biopsy to predict lobes without significant cancer: application in patient selection for hemiablative focal therapy.

Authors:  Jin-Woo Jung; Byung Ki Lee; Won Suk Choi; Yong Hyun Park; Sangchul Lee; Seong Jin Jeong; Sang Eun Lee; Seok-Soo Byun
Journal:  Prostate Int       Date:  2014-03-30

9.  Optimizing patient selection for focal therapy-mapping and ablating the index lesion.

Authors:  James S Wysock; Herbert Lepor
Journal:  Transl Androl Urol       Date:  2018-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.